Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jun 12 2026 | Journal of Cardiac Failure Call for Papers: Focus Issue: The New Frontier of Heart Function in Women HFSA News Journal of Cardiac Failure Read More Jun 9 2026 | Cardiogenic Shock Management and Palliative Cardiology Featured in June Issue of Journal of Cardiac Failure HFSA News Journal of Cardiac Failure Press Release Read More Jun 8 2026 | Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio Industry News Industry Read More Jun 5 2026 | Phase III FIND CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non Diabetic Chronic Kidney Disease Industry News Industry Read More Jun 2 2026 | Welcoming May's New HFSA Members HFSA News Membership Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Jun 12 2026 | Journal of Cardiac Failure Call for Papers: Focus Issue: The New Frontier of Heart Function in Women HFSA News Journal of Cardiac Failure Read More
Jun 9 2026 | Cardiogenic Shock Management and Palliative Cardiology Featured in June Issue of Journal of Cardiac Failure HFSA News Journal of Cardiac Failure Press Release Read More
Jun 8 2026 | Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio Industry News Industry Read More
Jun 5 2026 | Phase III FIND CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non Diabetic Chronic Kidney Disease Industry News Industry Read More
